Want to see HK:1952 full AI Analyst Report?
1952 Stock Chart & Stats
HK$51.50
-HK$1.00(-2.24%)
At close: 4:00 PM EST
HK$51.50
-HK$1.00(-2.24%)
Day’s Range― - ―
52-Week RangeHK$22.70 - HK$75.15
Previous CloseN/A
Volume6.86M
Average Volume (3M)3.13M
Market Cap
HK$8.87B
Enterprise ValueHK$10.98K
Total Cash (Recent Filing)HK$2.73B
Total Debt (Recent Filing)HK$926.28M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 02, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding353,829,860
10 Day Avg. Volume4,149,807
30 Day Avg. Volume3,134,197
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)2.09
Price to Sales (P/S)6.51
P/FCF Ratio-64.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.73Price Target Upside2.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.76
Revenue Forecast (FY)HK$3.40B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA near-doubling of revenue year-over-year signals a durable commercial ramp and expanding market adoption. Sustained top-line growth supports operating leverage, funds further clinical/commercial investment, and increases the chance of reaching sustained profitability over the medium term.
High Gross MarginsA roughly 60% gross margin indicates strong product-level economics and pricing power versus peers. Durable gross margins create room to cover R&D and SG&A, improve potential operating leverage as revenue scales, and support long-term profitability once fixed costs normalize.
Solid Balance Sheet / Moderate LeverageA sizable equity base and low debt-to-equity provide funding flexibility for clinical and commercial programs without immediate refinancing pressure. This capitalization gives the company runway to convert revenue momentum into profit and reduces short-term solvency risk.
Bears Say
Negative Operating & Free Cash FlowPersistently negative operating and free cash flow means the business still consumes capital to run operations. Even with improvement versus 2024, continued cash burn forces dependence on balance sheet reserves or external financing, constraining long-term financial flexibility.
Ongoing UnprofitabilityA negative net margin shows the company has not yet converted strong revenue into sustainable earnings. Continued losses pressure return metrics, limit retained earnings accumulation, and mean profitability must improve materially for the business to be self-funding over the medium term.
Negative Returns To Shareholders HistoricallyPersistent negative ROE indicates the company has historically destroyed shareholder capital. This structural weakness raises the risk that future capital raises will be dilutive and that management must demonstrate a durable shift to positive returns before investor confidence and reinvestment costs normalize.
Everest Medicines Ltd. News
1952 FAQ
What was Everest Medicines Ltd.’s price range in the past 12 months?
Everest Medicines Ltd. lowest stock price was HK$22.70 and its highest was HK$75.15 in the past 12 months.
What is Everest Medicines Ltd.’s market cap?
Everest Medicines Ltd.’s market cap is HK$8.87B.
When is Everest Medicines Ltd.’s upcoming earnings report date?
Everest Medicines Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 32 days.
How were Everest Medicines Ltd.’s earnings last quarter?
Everest Medicines Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.139 earnings per share for the quarter, missing the consensus estimate of HK$0.116 by -HK$0.256.
Is Everest Medicines Ltd. overvalued?
According to Wall Street analysts Everest Medicines Ltd.’s price is currently Undervalued.
Does Everest Medicines Ltd. pay dividends?
Everest Medicines Ltd. does not currently pay dividends.
What is Everest Medicines Ltd.’s EPS estimate?
Everest Medicines Ltd.’s EPS estimate is -1.08.
How many shares outstanding does Everest Medicines Ltd. have?
Everest Medicines Ltd. has 353,829,860 shares outstanding.
What happened to Everest Medicines Ltd.’s price movement after its last earnings report?
Everest Medicines Ltd. reported an EPS of -HK$0.139 in its last earnings report, missing expectations of HK$0.116. Following the earnings report the stock price went down -4.725%.
Which hedge fund is a major shareholder of Everest Medicines Ltd.?
Currently, no hedge funds are holding shares in HK:1952
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Everest Medicines Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.26%
Trailing 12-Months
Company Description
Everest Medicines Ltd.
Everest Medicines Limited operates as a biopharmaceutical firm, concentrating its efforts on bringing innovative treatments to market. The company handles the entire process, from identifying and acquiring promising drug candidates to developing them through clinical trials and ultimately commercializing them. Its core objective is to address significant gaps in existing medical treatments within the broader Asia Pacific region, with a particular focus on Greater China. The company boasts a strong portfolio, including eleven experimental drug candidates currently undergoing clinical evaluation. These investigational therapies are designed to combat a range of serious conditions, including various forms of cancer (oncology), immune system disorders (immunology), heart and kidney ailments (cardio-renal), and infectious diseases. Everest Medicines Limited was founded in 2017 and is based in Shanghai, China.
1952 Stock 12 Month Forecast
Average Price Target
HK$52.73
▲(2.39% Upside)
Technical Analysis
Zai Lab Ltd
―
Antengene Corporation Limited
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―